CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 28 enrolled
Drug / intervention
Insulin Peglispro +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02152384
NCT02152384Phase 1Completed

The Effect of Treatment With Basal Insulin Peglispro or Insulin Glargine on the Dose Response Effect of Prandial Insulin Lispro in Patients With Type 1 Diabetes Mellitus.

Eli Lilly and Company·interventional·Posted Jun 2, 2014·Updated Mar 1, 2019

In Brief

A Phase 1 clinical trial evaluating Insulin Peglispro, Insulin Lispro, and 1 other intervention for Diabetes Mellitus, Type 1. Completed, enrolled 28 participants across 1 site.

Detailed Summary

This study will look into how a base dose of insulin peglispro and insulin glargine will affect the meal time dose and efficacy of insulin lispro in type 1 diabetics.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 2, 2014
Enrollment StartJun 1, 2014
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 12.1 years ago

Interventions

Insulin Peglisprodrug

Administered SC

Insulin Lisprodrug

Administered SC

Insulin Glarginedrug

Administered SC